# Regeneron 的 maftivimab、Mapp 的 MBP134 及 Gilead 的 remdesivir 應在感染 Bundibugyo 型伊波拉病毒的患者中進行試驗。

*biotech · news · 2026-05-29 · Pharmaphorum*

## Key points

- WHO 建議將 Regeneron 的 maftivimab 作為 Bundibugyo 伊波拉病毒的單一療法進行測試。
- Gilead 的 obeldesivir 被 WHO 優先用於 Bundibugyo 伊波拉病毒的暴露後預防。
- WHO 確認兩款新的疫苗候選—rVSV Bundibugyo 與 ChAdOx1 Bundibugyo—需要進一步的臨床前研究。
- 目前 WHO 批准的伊波拉疫苗 MSD 的 Ervebo，可能無法有效保護 Bundibugyo 亞型。

The World Health Organization (WHO) has identified drugs from Regeneron, Mapp Bio, and Gilead Sciences that should be fast-tracked through clinical testing to respond to the current outbreak. The UN health agency's independent experts have said Regeneron's maftivimab, Mapp's MBP134, and Gilead's remdesivir should be trialled in patients infected with the Bundibugyo form of Ebola currently infecting more than 1,000 people in the Democratic Republic of the Congo (DRC), with cases also reported in neighbouring Uganda. At last count, the Bundibugyo outbreak had led to 10 confirmed deaths, with another 223 suspected, although the WHO has said it could be much larger as the virus is thought to have circulated undetected for some time. It has an estimated fatality rate of 24.6%, lower than the average of 50% observed across all Ebola outbreaks since the 1970s. Regeneron said that maftivimab is the most potent of the three antibodies included in its already-approved Inmazeb Ebola therapy, adding that the WHO has recommended it be studied as a monotherapy in the current outbreak, and supplies are already available for that purpose. Mapp's MBP134, meanwhile, is another antibody billed as a 'pan-Ebola' candidate designed to cover the four species that are known to infect humans. Remdesivir, an antiviral, was an important part of the response to the COVID-19 pandemic, and the WHO would like to see trials of the drug as a monotherapy and in combination with the two antibodies. Prophylaxis candidates Turning to prevention, the WHO has identified Gilead's obeldesivir – a follow-up to remdesivir that has been shown in non-human primates to be protective against lethal Ebola infection – as its priority candidate for post-exposure prophylaxis. For large-scale vaccination purposes, it has identified the single-dose rVSV Bundibugyo vaccine being developed by the International AIDS Vaccine Initiative (IAVI) and Oxford University/Serum Institute of India's ChAdOx1 Bundibugyo as the most promising candidates at the moment. However, both those vaccines need additional preclinical work to be carried out before they will be ready for human testing. New vaccines are needed because the current shot pre-qualified by the WHO for use in Ebola outbreaks – MSD's Ervebo – targets the more common Zaire species and may not provide good protection against Bundibugyo. The WHO said this "should not be used outside carefully designed research settings, to allow for its performance against [Bundibugyo virus disease] to be assessed." In its update, the agency said it is "working closely with the governments of the Democratic Republic of the Congo and Uganda to facilitate the implementation of research evaluation of these products."

**Companies:** Gilead Sciences, Regeneron, Mapp Bio
**Countries:** Democratic Republic of the Congo, Uganda

[Read the full story on Pharmaphorum](https://pharmaphorum.com/news/who-names-three-priority-ebola-drugs-trials)

---

Canonical: https://newsio.io/zh-TW/n/f5b638b2-bb5f-4cd6-a0d3-89f8c3098cfb/regeneron-maftivimabmapp-mbp134-gilead-remdesivir-bundibugyo
Summarized by Newsio from Pharmaphorum. https://newsio.io/how-it-works